Clinical trial · Observational
microRNA Profile in Early-stage Cervical Cancer
microRNA Profile Associated With Positive Lymph Node Metastasis in Early-stage Cervical Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Persistent infections with high-risk subtypes of the human papillomavirus (HPV) are recognized as the etiological factor for developing cervical cancer. The aim od this study was to identify a miRNA profile in patients with early-stage cervical cancer with positive lymph node metastasis treated. Formalin-fixed paraffin-embedded (FFPE) tissue samples of patients with a diagnosis of early-stage cervical cancer treated by radical hysterectomy with lymphadenectomy were collected.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Positive metastasis
- description
- Positive occult lymph node metastasis pathology
- label
- Negative metastasis
- description
- Without lymph node metastasis pathology
Primary outcomes (1)
- measure
- Prognostic miRNAs
- timeFrame
- 7 years
- description
- Identify a subset of miRNAs with prognostic value associated with early-stage CC patients treated with RH and BPL with positive lymph node metastasis.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Cervical cancer histopathological diagnosis * Clinical stage IB1 or IIA1 CC * Treated with radical hysterectomy (RH) with bilateral pelvic lymphadenectomy (BPL) Exclusion Criteria: * Double primary tumors * Treatment regimens other than standard treatment * Poor quality formalin-fixed paraffin-embedded tissue blocks
References
Publications (10)
- BACKGROUNDThomison J 3rd, Thomas LK, Shroyer KR. Human papillomavirus: molecular and cytologic/histologic aspects related to cervical intraepithelial neoplasia and carcinoma. Hum Pathol. 2008 Feb;39(2):154-66. doi: 10.1016/j.humpath.2007.11.002. PMID 18206494
- BACKGROUNDKoh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Cohn D, Crispens MA, DuPont N, Eifel PJ, Gaffney DK, Giuntoli RL 2nd, Han E, Huh WK, Lurain JR 3rd, Martin L, Morgan MA, Mutch D, Remmenga SW, Reynolds RK, Small W Jr, Teng N, Tillmanns T, Valea FA, McMillian NR, Hughes M; National Comprehensive Cancer Network. Cervical cancer. J Natl Compr Canc Netw. 2013 Mar 1;11(3):320-43. doi: 10.6004/jnccn.2013.0043. PMID 23486458
- BACKGROUNDLea JS, Lin KY. Cervical cancer. Obstet Gynecol Clin North Am. 2012 Jun;39(2):233-53. doi: 10.1016/j.ogc.2012.02.008. Epub 2012 Apr 24. PMID 22640713
- BACKGROUNDDelgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1990 Sep;38(3):352-7. doi: 10.1016/0090-8258(90)90072-s. PMID 2227547
- BACKGROUNDSuprasert P, Charoenkwan K, Khunamornpong S. Pelvic node removal and disease-free survival in cervical cancer patients treated with radical hysterectomy and pelvic lymphadenectomy. Int J Gynaecol Obstet. 2012 Jan;116(1):43-6. doi: 10.1016/j.ijgo.2011.08.001. Epub 2011 Oct 5. PMID 21978816
- BACKGROUNDTogami S, Kamio M, Yanazume S, Yoshinaga M, Douchi T. Can pelvic lymphadenectomy be omitted in stage IA2 to IIB uterine cervical cancer? Int J Gynecol Cancer. 2014 Jul;24(6):1072-6. doi: 10.1097/IGC.0000000000000163. PMID 24905616
- BACKGROUNDTanaka Y, Sawada S, Murata T. Relationship between lymph node metastases and prognosis in patients irradiated postoperatively for carcinoma of the uterine cervix. Acta Radiol Oncol. 1984;23(6):455-9. doi: 10.3109/02841868409136048.